BluePrint, an 80-gene assay that stratifies tumours into three molecular subtypes (luminal, basal, and HER2), can be used in combination with MammaPrint to characterize luminal tumours as luminal A (low risk) or luminal B (high risk)55. Here, ERBB2 is linked to neoplasm.